Rational Monitoring of Prostate - Specific Antigen ( PSA ) after Radical Prostatectomy . Student
نویسندگان
چکیده
.......................................................................................................................................................................................................................3 Introduction.............................................................................................................................................................................................................4 Method..........................................................................................................................................................................................................................6 1. Patient recruitment and data collection...................................................................................................................................6 2. Population description......................................................................................................................................................................7 3. Relationship between clinical markers and relapse...........................................................................................................7 4. PSA database description.................................................................................................................................................................7 5. PSADTcalculation and predictive performance....................................................................................................................9 Results.......................................................................................................................................................................................................................11 1. Descriptive Analysis........................................................................................................................................................................11 1.1. Study Population.............................................................................................................................................................11 1.2. Relation between clinical markers and outcomes (univariate analysis).........................................................12 1.3. Prediction of outcome by clinical markers (multivariate approach)................................................................14 2. Assessment of PSA post-operative Monitoring..................................................................................................................14 2.1. Time of postoperative PSA determinations .................................................................................................14 2.2. Postoperative PSA trajectories.....................................................................................................................................16 2.3. Variogram of PSA evolution..........................................................................................................................................18 2.4. PSA responsiveness to re-intervention......................................................................................................................19 3. PSA doubling time............................................................................................................................................................................20 3.1. Determination of PSA doubling time (PSADT) ...........................................................................................20 3.2. PSADT log slope method versus 2-points method (univariate approach).................................................21 4. Predictive value of PSADT regarding cancer relapse......................................................................................................21 4.1. PSADT predictive value at 6 month, 1 year, 2 years and 3 years after RP (univariate approach).............21 4.2. Predictive value of PSADT cut-offs (univariate approach)..................................................................................22 4.3 Added value of PSADT in outcome prediction (multivariate approach)...........................................................22 Discussion...............................................................................................................................................................................................................24 References................................................................................................................................................................................................................27 Master’s thesis No 110 Hugo Teixeira Farinha
منابع مشابه
The possibility of hormone-mediated PSA derangement in prostate cancer treatment
Background: This study was designed to suggest the possibility of hormone-related derangement in salvage radiotherapy (SRT) after radical prostatectomy in terms of prostate-specific antigen (PSA) control. Materials and Methods: Among 160 consecutive prostate cancer patients who received radical prostatectomy, 34 with SRT between 2004 and 2012 were retrospectively reviewed. The numbers of patien...
متن کاملArtificial prostate-specific antigen persistence after radical prostatectomy.
Introduction Serum prostate-specific antigen (PSA) is of paramount importance as a diagnostic tool for the detection, staging, and monitoring of patients with prostate cancer. Because PSA is organ but not disease specific, it has certain limitations as a screening test for prostate cancer. After radical prostatectomy (RP), however, PSA is an excellent tumor marker with a high sensitivity and sp...
متن کاملUltrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy.
We used an ultrasensitive prostate-specific antigen (PSA) assay with a detection limit of 0.02 microgram/L for long-term monitoring of PSA changes in 5 patients who were cured by radical prostatectomy and in 10 patients who had failed prostatectomies; 5 patients who underwent cystoprostatectomy were also evaluated with one sample after surgery. Relapse-free periods, determined on the basis of c...
متن کاملPSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملProstate-specific Antigen: Its Usefulness in Clinical Medicine.
Prostate-specific antigen (PSA) was discovered about 20 years ago and over the last decade it has become the premier tumor marker for diagnosis, monitoring and prognosis of prostatic carcinoma. PSA is now considered to be the best tumor marker available in clinical medicine. It is the only tumor marker that has been approved by the Food and Drug Administration of the USA for mass screening: for...
متن کامل